Login to Your Account



Heat Biologics shares melt as cancer vaccine disappoints

By Michael Fitzhugh
Staff Writer

Thursday, December 1, 2016

Top-line data from a trial of HS-410 (vesigenurtacel-L), Heat Biologics Inc.'s experimental non-muscle invasive bladder cancer (NMIBC) vaccine, fell short of hitting its primary endpoint in a phase II study, robbing the Durham, N.C.-based company of a desired chance to seek an accelerate approval in phase III, but not of its hope for success, CEO and founder Jeff Wolf told BioWorld Today.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription